PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-4.59%
Both companies show declining cash positions (-4.59% vs TRVN's -10.61%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
-40.54%
Short-term investments yoy growth below half of TRVN's 107.18%. Michael Burry might see potential liquidity risk. Investigate alternative capital uses or constraints.
-4.61%
Below half of TRVN's 58.84%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of TRVN's 58.45%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
10.64%
Below half TRVN's -1.29%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.58%
Below half of TRVN's -1.09%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half of TRVN's 58.05%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.14%
Less than half of TRVN's -41.88%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x TRVN's -25.00%. David Dodd sees stronger subscription/prepayment demand.
-34.95%
Exceeding 1.5x TRVN's -0.61%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-29.36%
Above 1.5x TRVN's -18.79%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.36%
Above 1.5x TRVN's -15.53%. Michael Burry sees a potential leverage warning sign.
3.53%
Less than half of TRVN's 20.63%. David Dodd sees fewer share issuances vs. competitor.
-3.88%
0.5-0.75x TRVN's -6.79%. Martin Whitman is wary of weaker retention or lower profitability.
-25.46%
Less than half of TRVN's 319.72%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.65%
Below half TRVN's 70.20%. Michael Burry sees potential underperformance in building shareholder capital.
-4.86%
Below half TRVN's 58.05%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-40.54%
Below half TRVN's 107.18%. Michael Burry suspects major underinvestment or forced divestment.
-100.00%
Less than half of TRVN's 1.61%. David Dodd sees less overall debt expansion vs. competitor.
4.24%
Less than half of TRVN's 11.12%. David Dodd sees better deleveraging or stronger cash buildup than competitor.